Gossamer Bio Stock Forecast, Price & News

-0.06 (-0.70 %)
(As of 06/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume385,971 shs
Average Volume600,245 shs
Market Capitalization$642.96 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GOSS News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

Gossamer Bio logo

About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.66 out of 5 stars

Medical Sector

372nd out of 2,105 stocks

Pharmaceutical Preparations Industry

171st out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions

Is Gossamer Bio a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Gossamer Bio stock.
View analyst ratings for Gossamer Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Gossamer Bio?

Wall Street analysts have given Gossamer Bio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Gossamer Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Gossamer Bio's next earnings date?

Gossamer Bio is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Gossamer Bio

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) released its earnings results on Thursday, May, 6th. The company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.77) by $0.01.
View Gossamer Bio's earnings history

How has Gossamer Bio's stock been impacted by COVID-19?

Gossamer Bio's stock was trading at $10.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GOSS shares have decreased by 20.0% and is now trading at $8.47.
View which stocks have been most impacted by COVID-19

What price target have analysts set for GOSS?

6 Wall Street analysts have issued 12-month price targets for Gossamer Bio's shares. Their forecasts range from $18.00 to $29.00. On average, they anticipate Gossamer Bio's stock price to reach $23.00 in the next year. This suggests a possible upside of 171.5% from the stock's current price.
View analysts' price targets for Gossamer Bio
or view top-rated stocks among Wall Street analysts.

Who are Gossamer Bio's key executives?

Gossamer Bio's management team includes the following people:
  • Mr. Faheem Hasnain, Co-Founder, CEO, Pres & Chairman (Age 63, Pay $278.56k)
  • Mr. Bryan Giraudo, Chief Financial Officer (Age 45, Pay $593.07k)
  • Mr. Christian Waage, Exec. VP, Gen. Counsel & Sec. (Age 54, Pay $568.46k)
  • Dr. Laura L. Carter, Chief Scientific Officer (Age 54)
  • Ms. Deanna Weber, Sr. VP of HR
  • Dr. Richard Aranda, Sr. VP of Clinical Devel.
  • Ms. Caryn L. Peterson, Exec. VP of Regulatory Affairs (Age 62)
  • Dr. Larry Zisman M.D., Sr. Director of Clinical Devel.
  • Dr. Robert F. Roscigno, VP of Clinical Devel. (Age 55)
  • Mr. Mario Orlando, VP of Commercial New Product Planning

Who are some of Gossamer Bio's key competitors?

What other stocks do shareholders of Gossamer Bio own?

When did Gossamer Bio IPO?

(GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO.

What is Gossamer Bio's stock symbol?

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.07%), Federated Hermes Inc. (4.56%), Palo Alto Investors LP (2.34%), Octagon Capital Advisors LP (1.86%), Goldman Sachs Group Inc. (1.29%) and Nuveen Asset Management LLC (1.24%). Company insiders that own Gossamer Bio stock include Bryan Giraudo, Faheem Hasnain, Fund V Gp LP Omega, Jakob Dupont, Luisa Salter-Cid and Waage Christian.
View institutional ownership trends for Gossamer Bio

Which institutional investors are selling Gossamer Bio stock?

GOSS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Octagon Capital Advisors LP, Northern Trust Corp, Credit Suisse AG, Ensign Peak Advisors Inc, Renaissance Technologies LLC, Squarepoint Ops LLC, and Morgan Stanley. Company insiders that have sold Gossamer Bio company stock in the last year include Bryan Giraudo, and Luisa Salter-Cid.
View insider buying and selling activity for Gossamer Bio
or view top insider-selling stocks.

Which institutional investors are buying Gossamer Bio stock?

GOSS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Parkman Healthcare Partners LLC, Nuveen Asset Management LLC, Alyeska Investment Group L.P., Rafferty Asset Management LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Gossamer Bio stock in the last two years include Bryan Giraudo, Faheem Hasnain, and Waage Christian.
View insider buying and selling activity for Gossamer Bio
or or view top insider-buying stocks.

How do I buy shares of Gossamer Bio?

Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gossamer Bio's stock price today?

One share of GOSS stock can currently be purchased for approximately $8.47.

How much money does Gossamer Bio make?

Gossamer Bio has a market capitalization of $642.96 million. The company earns $-243,360,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis.

How many employees does Gossamer Bio have?

Gossamer Bio employs 195 workers across the globe.

What is Gossamer Bio's official website?

The official website for Gossamer Bio is

Where are Gossamer Bio's headquarters?

Gossamer Bio is headquartered at 3013 SCIENCE PARK, SAN DIEGO CA, 92121.

How can I contact Gossamer Bio?

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company can be reached via phone at 858-922-0718 or via email at [email protected]

This page was last updated on 6/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.